Shares Investor Evening


Abzena (ABZA)

Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceutical products. The development of biopharmaceuticals is a growing area and requires specialist technology and expertise. 
The Group comprises Antitope, PacificGMP, PolyTherics and TCRS, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups. 

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture. 

PacificGMP provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies. 

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
TCRS is a contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards. 

Abzena (AIM: ABZA) has its main operations in Cambridge, UK, San Diego, CA, US and Bristol, Pennsylvania, US . For more information, please see

Horizon Discovery (HZD)

Horizon Discovery is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer. These models have been adopted by c1,400 unique organisations to better understand of the genetic drivers of disease, and by Horizon in a range of services offered to customers as well as in the Company’s own R&D pipeline. 

Martin & Co (MCO)

With a network of almost 200 offices, Martin & Co is one of the largest franchised property businesses in the UK. Established in 1986, it provides a responsive local letting and sales service with the backing of a national brand.The company has a strong focus on lettings and currently manages 30,000 properties on behalf of private clients, which amounts to a town the size of Maidenhead in Berkshire. In March 2012, Martin & Co introduced an estate agency service with a view to leverage and extend its established brand name in the UK. The company's approach to estate agency differs from standard commission based estate agent sales models, in that it offers an option for vendors to instruct it on a pay-as-you-go basis, depending on which services they require.

Midatech Pharma (MTPH)

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.